

AD-A235 922



2

INSTITUTE REPORT NO. 456

Concentration and Molecular Size Distribution of
Dextran in Serum from Rabbits and Dogs Infused
with Hypertonic Saline Dextran

M.A. Dubick,
J.J. Summary,
G.M. Zaucha,
J.W. Pfeiffer,
D.W. Korte Jr.
and C.E. Wade

DTIC
ELECTE
MAY 24 1991
S B D

Division of Military Trauma Research


DISTRIBUTION STATEMENT A

Approved for public release;
Distribution Unlimited

91-00271



October 1990



LETTERMAN ARMY INSTITUTE OF RESEARCH PRESIDIO OF SAN FRANCISCO CALIFORNIA 94129

91 5 22 066

Concentration and Molecular Size Distribution of Dextran in Serum from Rabbits and Dogs Infused with Hypertonic Saline Dextran, M.A. Dubick et al


This document has been approved for public release and sale; its distribution is unlimited.

Destroy this report when it is no longer needed. Do not return to the originator.


Citation of trade names in this report does not constitute an official endorsement or approval of the use of such items.

The experimental studies of the author described in this report were reviewed and approved by the Institutional Review Committee/Animal Care and Use Committee at Letterman Army Institute of Research. The Manuscript was peer reviewed for compliance prior to submission for publication. In conducting the research described here, the author adhered to the "Guide for the Care and Use of Laboratory Animals," DHEW Publication (NIH) 85-23.

This material has been reviewed by Letterman Army Institute of Research and there is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. (AR 360-5)


DONALD G. CORBY

COL, MC
Commander


(date)

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188		
1a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED			1b. RESTRICTIVE MARKINGS			
2a. SECURITY CLASSIFICATION AUTHORITY			3. DISTRIBUTION / AVAILABILITY OF REPORT Approved for public release distribution is unlimited.			
2b. DECLASSIFICATION / DOWNGRADING SCHEDULE						
4. PERFORMING ORGANIZATION REPORT NUMBER(S) Institute Report No. 456			5. MONITORING ORGANIZATION REPORT NUMBER(S)			
6a. NAME OF PERFORMING ORGANIZATION Letterman Army Institute of Research		6b. OFFICE SYMBOL (If applicable) SGRD-ULT-M	7a. NAME OF MONITORING ORGANIZATION U.S. Army Medical Research and Development Command			
6c. ADDRESS (City, State, and ZIP Code) Division of Military Trauma Research, LAIR Presidio of San Francisco, CA 94129-6800			7b. ADDRESS (City, State, and ZIP Code) Ft. Detrick, Frederick, MD 21701			
8a. NAME OF FUNDING / SPONSORING ORGANIZATION		8b. OFFICE SYMBOL (If applicable)	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER			
8c. ADDRESS (City, State, and ZIP Code)			10. SOURCE OF FUNDING NUMBERS			
			PROGRAM ELEMENT NO. 63807A	PROJECT NO. D836	TASK NO. AX	WORK UNIT ACCESSION NO. 087
11. TITLE (Include Security Classification) (U) Concentration and Molecular Size Distribution of Dextran in Serum from Rabbits and Dogs Infused with Hypertonic Saline Dextran						
12. PERSONAL AUTHOR(S) M.A. Dubick, J.J. Summarv, G.M. Zaucha, J.W. Pfeiffer, D.W. Korte, C.E. Wade						
13a. TYPE OF REPORT Institute		13b. TIME COVERED FROM _____ TO _____		14. DATE OF REPORT (Year, Month, Day) October 1990		15. PAGE COUNT 17
16. SUPPLEMENTARY NOTATION						
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)			
FIELD	GROUP	SUB-GROUP	(U) Dextran-70, rabbits, dogs, hypertonic, resuscitation (U)			
19. ABSTRACT (Continue on reverse if necessary and identify by block number) The present study evaluated serum dextran concentration and its molecular size distribution following infusion of 7.5% NaCl/Dextran-70 (HSD) or Dextran-70 alone (D-70) at doses as high as the maximum tolerated dose (MTD). In the first set of experiments beagle dogs were infused i.v. with a single MTD of HSD or D-70 (20ml/kg). At 6h post-infusion, serum dextran concentrations were 15% higher in the D-70 group than the HSD group, but no significant differences were detected at the later times. In other studies, daily infusion of 2,3, or 4 times a 4 ml/kg dose of HSD or D-70 for 14 d in rabbits resulted in a dose-dependent, progressive rise in plasma dextran concentration. Molecular sizing of dextran in serum at 14 d revealed a shift from 70,000 to 90,000 M.W., reflecting the typical retention of the larger dextran fractions seen following a single bolus infusion. Despite the repeated infusions, molecular size distribution of						
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS			21. ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED			
22a. NAME OF RESPONSIBLE INDIVIDUAL Donald G. Corby, COL, MC			22b. TELEPHONE (Include Area Code) (415) 561-3600		22c. OFFICE SYMBOL SGRD-ULZ	

dextran in serum indicated no impairment in excretion of lower molecular weight components. With repeated dosing no significant differences were observed between dextran concentrations following HSD or D-70 infusions. Since serum dextran concentrations reflected the dose infused, the data from these studies suggest that serum dextran concentrations are a useful index of dextran administration and clearance. Despite the high concentrations and loads infused, no adverse effects on any of the animals were detected.

Concentration and Molecular Size Distribution
of Dextran in Serum from Rabbits and Dogs
Infused with Hypertonic Saline Dextran

Michael A. Dubick, Ph.D., James J. Summary, Ph.D.,
Gary M. Zaucha, D.V.M. MAJ, VC, Juergen W. Pfeiffer,
M.S., Donald W. Korte, Jr., Ph.D., LTC, MSC and
Charles E. Wade, Ph.D.

Division of Military Trauma Research
Letterman Army Institute of Research
Presidio of San Francisco, CA 94129-6800

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	



ABSTRACT

The present study evaluated serum dextran concentration and its molecular size distribution following infusion of 7.5% NaCl/Dextran-70 (HSD) or Dextran-70 alone (D-70) at doses as high as the maximum tolerated dose (MTD). In the first set of experiments beagle dogs were infused i.v. with a single MTD of HSD or D-70 (20ml/kg). At 6h post-infusion, serum dextran concentrations were 15% higher in the D-70 group than the HSD group, but no significant differences were detected at the later times.

In other studies, daily infusion of 2,3, or 4 times a 4 ml/kg dose of HSD or D-70 for 14 d in rabbits resulted in a dose-dependent, progressive rise in plasma dextran concentration. Molecular sizing of dextran in serum at 14 d revealed a shift from 70,000 to 90,000 M.W., reflecting the typical retention of the larger dextran fractions seen following a single bolus infusion. Despite the repeated infusions, molecular size distribution of dextran in serum indicated no impairment in excretion of lower molecular weight components. With repeated dosing no significant differences were observed between dextran concentrations following HSD or D-70 infusions. Since serum dextran concentrations reflected the dose infused, the data from these studies suggest that serum dextran concentrations are a useful index of dextran administration and clearance. Despite the high concentrations and loads infused, no adverse effects on any of the animals were detected.

Concentration and Molecular Size Distribution of
Dextran in Serum from Rabbits and Dogs Infused with
Hypertonic Saline Dextran
-- Dubick et al.

INTRODUCTION

Recent years have seen a renewed interest in the use of dextrans for the treatment of hypovolemia. In particular, a 7.5% NaCl/6% Dextran-70 (HSD) solution has generated numerous experimental studies (1-4) and with reports of potential clinical efficacy in trauma patients (5), HSD is currently undergoing Phase III clinical trials in the U.S.

At present the proposed therapeutic dose of HSD is 4ml/kg or infusion of 250ml to an average 70kg adult. However, others have proposed that 4ml/kg of a 12% Dextran-70 solution may be more efficacious (6) and a smaller dose of 24% Dextran-70 solution has even been proposed (7). However, questions remain regarding the metabolic fate of the infused dextran. Despite the large body of literature on dextran metabolism that has accumulated over the past 40 years (8,9), few studies have addressed the newer Dextran-70 preparations and its narrower molecular weight range, particularly in the presence of hypertonic saline.

Previous investigations with dextrans reported that they were primarily excreted through the kidney (10,11). Glomerular filtration of dextrans with molecular weights > 50-60,000 was very low and dextran was neither reabsorbed nor secreted by the renal tubules (10,12,13). Studies in normal humans have shown that 31-47% of a dose of Dextran-60 or 70 was excreted in urine in the first 24h (10,14,15). Most recently Holcroft, et al. (5) reported that approximately 30% of the dextran remained in plasma 24h following infusion of HSD to trauma victims. In work from our own laboratory, we have observed in experimental animals that the $t_{1/2}$ of dextran in serum was about 7.4 hr in rabbits and 10-12 hr in pigs, following infusion of 4ml/kg HSD (16,17).

The present study monitored dextran metabolism in serum in anticipation of a modified HSD dose or formulation, or expanded uses, such as by multiple dosing. Rabbits and dogs were infused once or daily with doses up to the maximum tolerated dose (MTD) of HSD or Macrodex (Dextran-70 in 0.9% NaCl). Serum concentrations and molecular size distribution of dextran were determined to evaluate the potential for dextran accumulation in the body.

MATERIALS AND METHODS

Animals and Treatment

Dogs: Male (n=4) and female (N=4) beagle dogs, weighing initially 7.5 to 10.9 kg, were obtained from Ridgman Farms, Inc. (Mt. Horeb, WI). They were individually housed in stainless steel runs and fed Purina Canine Diet 5007 and purified water, ad libitum. Dogs were housed in a room controlled for temperature (15.6°-26.7°C) and humidity (10-65%) with a 12 hr photoperiod (0600-1800 hours). All animals were acclimated for at least 12 d before the day of dosing. During this period dogs were quarantined, examined and baseline hematologic and serum chemistry were performed. They were checked daily for signs of illness. For the daily dosing studies, 12 beagle dogs (6 male, 6 female), weighing 8.7-14.4 kg were obtained from Hazelton-LRE (Kalamazoo, MI). Otherwise, animal husbandry conditions were the same.

Rabbits: Male (n=30) and female (n=30) New Zealand White rabbits initially weighing 2.3-3.6 kg were obtained from Hazelton Research Products (Denver, PA). Rabbits were individually housed in stainless steel cages with screen bottoms and fed Purina rabbit chow 5322 and purified water ad libitum. Animals were housed in a room controlled for temperature and humidity as described above for dogs. All animals were checked daily for illness. Water intake was measured daily and body weights were recorded weekly throughout the 14 day study.

Treatment

All animals were randomly assigned to treatment groups. In both dogs and rabbits, preliminary studies were performed to determine the maximum tolerated dose (18,19). In the single dose studies dogs were infused i.v. via the cephalic or saphenous vein with the maximum tolerated dose (MTD) of 20 ml/kg 7.5% NaCl/6% Dextran-70 (HSD) or 6% Dextran-70 (D-70) (AB Pharmacia, Uppsala, Sweden). In the studies where dogs received daily infusions with doses as high as the MTD of HSD or D-70, solutions were administered via surgically implanted femoral vein catheters. Rabbits were also infused daily via surgically implanted femoral vein catheters at doses up to the MTD of HSD or D-70, previously determined to be 16 ml/kg. All infusions were administered over a 5 min period.

In dogs infused with the single dose of HSD or D-70, blood samples were withdrawn prior to and 0.25, 1, 2, 3, 7 and 14 days following infusion. In both rabbit and dog multiple dosing studies, blood samples were withdrawn prior to dosing (baseline) and on days 1, 2, 3, 7 and 14 at a time before the subsequent infusion. Serum was separated from blood cells by centrifugation and stored at -20°C until analyzed.

Dextran Measurements

Total carbohydrate concentrations in serum were determined by the anthrone reaction (20) following precipitation of serum protein with 10% trichloroacetic acid (TCA). Plasma glucose was determined by an automated glucose-hexokinase enzymatic method performed by the Analytical Chemistry Branch, Letterman Army Institute of Research. Plasma dextran concentrations were then estimated by subtracting the glucose concentrations from the concentrations of total carbohydrate. Hematocrit values were determined to monitor the hemodilution effects of HSD and D-70.

Gel Filtration

Serum samples were deproteinized with TCA, neutralized and the protein-free aliquot applied to a 0.9 x 87 cm column of Sephadex 200/100 equilibrated with 0.3% NaCl and eluted with the same solution (21). Fractions were collected and assayed for anthrone-reactive substances as described above. These studies quantitated the molecular weight distribution of the dextran fractions to detect metabolism of dextran following its infusion as HSD or D-70.

Other Assays

Assays for sodium, potassium and chloride were performed by the Analytical Chemistry Branch, Letterman Army Institute of Research. Serum sodium and potassium concentrations were determined with a flame photometer (Instrumentation Laboratory, Lexington, MA). Chloride concentrations were determined by a commercial kit (Roche Diagnostic Systems, Nutley, NJ) for analysis on a Cobas Fara II centrifugal fast analyzer (Roche Analytical Instruments, Belleville, NJ).

Statistical Analysis

Data were statistically analyzed by standard one-way ANOVA with time as the independent variable. At each time period, if a significant F- statistic was obtained, differences between groups were evaluated by Dunnett's or Newman Keuls multiple range test (22). A $p < 0.05$ was considered the level of statistical significance.

RESULTS

Single dose in dogs

The single infusion of HSD or D-70 at the MTD (20 ml/kg) did not affect body weight during the experimental period (data not shown). Water consumption increased nearly 3-fold ($2019 \pm$ vs. 699 ± 208 ml/day) the first day after HSD infusion in comparison to baseline values in this group. No such increase in water consumption was observed in dogs following D-70 infusion. Since these animals were euvolemic, infusion of HSD or D-70 had no significant effect on hematocrits at any of the times assayed (Table 1). During the experimental period D-70 infusion had no significant effect on serum Na, K or Cl concentrations (Table 1). In contrast, 6 hr after HSD infusion, serum Na was significantly higher and K lower, in comparison to baseline concentrations (Table 1). At 24h, the concentrations of these elements were normal and remained so throughout the remaining experimental period. Serum Cl concentrations were not affected by HSD administration.

In dogs infused with a single dose of 20ml/kg HSD or D-70, serum dextran concentrations 6h after infusions were 15% higher in the D-70 than HSD group (Table 2). No significant differences were detected in serum dextran concentrations between groups at all other time points.

Multiple dose in dogs

Daily infusions of HSD or D-70 for 14 days at doses up to 20ml/kg also did not affect body weights. At all doses of HSD, daily water consumption was significantly higher than pre-infusion levels throughout the 14 day experimental period whereas water consumption was not affected by daily D-70 infusions (data not shown). In these animals, daily infusion of

HSD and D-70 at the MTD resulted in significantly lower hematocrits in comparison to pre-infusion values (Table 3). In both HSD and D-70 infused dogs, no significant effects on serum Na, K, or Cl concentrations were observed throughout the experimental period (Table 3).

Daily infusion of 12, 16, or 20 ml/kg HSD or D-70 resulted in a dose-dependent, progressive increase in serum dextran concentrations (Fig 1). In general dextran concentrations were similar in the dogs infused with 16 or 20 ml/kg and these concentrations were significantly higher than those measured in dogs infused with 12ml/kg. In addition, at each dose level, serum dextran concentrations on comparable days were slightly lower in dogs infused with HSD than D-70, but the differences were not statistically significant.

Multiple dosing in rabbits

Daily infusion of the MTD (16ml/kg) of HSD or D-70 for 14 days in rabbits also did not affect body weights throughout the experimental period. In contrast to dogs, daily infusion of the compounds also did not significantly affect water consumption (data not shown).

In the D-70 group, hematocrits were significantly lower than pre-infusion levels from day 2 to the end of the experimental period, whereas in the HSD group, hematocrits were significantly lower than pre-infusion values from day 3 to 14 (Table 3). In both groups, serum Na, K and Cl were not significantly affected by D-70 or HSD infusion at any of the times assayed (Table 3).

In rabbits infused daily with 8, 12 or 16ml/kg of HSD or D-70, a progressive dose-response increase in serum dextran concentrations was also observed over the 14-day experimental period (Fig 2). As observed in the dog studies, no significant differences in serum dextran concentrations were detected following infusion of the 12 or 16ml/kg dose, and these concentrations were higher than those observed following infusion of 8ml/kg. In addition, at each time period assayed, no significant differences were observed in serum dextran concentrations between animals receiving the same dose of HSD or D-70. Gel filtration chromatography of serum from rabbits infused daily with the MTD of 16 ml/kg showed the typical shift to the left, corresponding to a shift in peak molecular weights from 70,00 to 90,000 for both HSD and D-70 over the 14 day period (Fig 3). Despite the multiple infusions, there appeared to be no

decrement in the serum clearance of low molecular weight dextran components.

Discussion

Current experimentation with hypertonic/hyperoncotic solutions, e.g., HSD, for the treatment of hypovolemic states has led to 4 ml/kg as the recommended therapeutic dose (cf 16). More recently, others have begun experimenting with higher dextran or salt concentrations to derive a greater cardiodynamic benefit (6,7). As these studies have progressed, it has become clear that a better understanding of dextran metabolism, at varying NaCl and Dextran-70 loads, could help design more rational therapeutic approaches and avoid potentially adverse effects.

In the present study, 6h following infusion of a single bolus of the maximum tolerated dose of 20 ml/kg of HSD to euvoletic dogs, serum Na and K concentrations were significantly different than pre-infusion levels although peak concentrations were not determined. At 24h, Na and K concentration had returned to normal. This is in agreement with previous studies that have shown a peak rise in serum Na within minutes after an infusion of HSD or hypertonic saline, then a slow return of serum Na toward normal levels (2, 23-25). This return to baseline occurs more rapidly if the animals are allowed free access to water following HSD infusion, and under these conditions Na concentrations are normal by 24h post-infusion (23). Since animals in the present study were allowed free access to water, it is not surprising that serum Na concentrations are normal 24h after HSD infusion and that Na metabolism was not altered following daily HSD infusions for 14 d in either rabbits or dogs.

In addition, the decrease in serum K observed in dogs 6h following a single MTD of HSD was transient and was not clinically significant. Daily infusions of HSD or D-70 also did not affect serum K concentrations in rabbits or dogs. Serum Cl concentrations were not affected in either species during the 14 day experimental period.

At the 6h time point in the single-dose study, serum dextran concentrations were approximately 15% higher in dogs infused with Dextran-70 (D-70) than HSD. It was possible that this difference reflected a greater hemodilution induced by HSD than D-70, but this was not supported by the hematocrit values obtained.

Although body weights were not statistically different between the groups, the D-70 group consistently weighed a little more, so these initial differences may reflect the D-70 group as a whole receiving more dextran than the HSD group. In general, this serum dextran concentration was 3-4 times higher than the 6h concentration observed in normal rabbits or pigs infused with 4 ml/kg HSD (16,17). Nevertheless, at the subsequent times, dextran concentrations were nearly identical in both groups for the remainder of the experimental period. In both the HSD and D-70 dogs, serum dextran concentrations were essentially undetectable 72h after infusion. In previous studies with rabbits and pigs infused with 4 ml/kg HSD, we observed serum $t_{1/2}$'s of 7.4 and 10-12 hr, respectively (16,17). Thus, the data from the present studies are consistent with these observations and suggest that although the dogs were infused with 5 times the dose of HSD or D-70 used previously, the rate of dextran clearance from serum did not appear to be altered.

In the second set of experiments, rabbits and dogs were infused daily for 14 d, i.v., with multiples of the 4 ml/kg dose, to their respective MTD. In preliminary studies this was determined to be 16 ml/kg for rabbits (19). Serum dextran concentrations were measured to see if dextran accumulation correlated with any observed toxicity. Based on the serum $t_{1/2}$ of dextran previously observed in rabbits (17), 24h was not long enough to totally clear a 4 ml/kg dextran dose from serum, so its accumulation was expected. A dose-response increase in serum dextran concentrations was observed in both HSD and D-70-infused rabbits. In both HSD and D-70-infused rabbits, at all doses, serum dextran concentrations were observed to increase about 4 to 6 times the corresponding concentrations determined on day 1.

This increase in dextran serum concentrations does not suggest a change in the rate of its serum clearance, despite daily infusion at the MTD. Further analysis of serum dextran in rabbits infused with 16ml/kg HSD and D-70 revealed a shift in higher molecular weight fractions from 70,000 to 90,000 over the 14 day period. This shift is consistent with previous reports following a single "therapeutic" dose of D-70 or HSD (26,17). The relatively small magnitude of the shift observed in the present study suggests that renal clearance of dextran was not significantly affected by daily infusion of such large doses. However, urine was not available in this study to confirm this hypothesis.

In conclusion, these data indicate that daily infusion of HSD or D-70, at doses as high as the maximal tolerated dose to rabbits and dogs resulted in serum dextran concentrations as high as 2500 mg/dl. In addition the serum concentrations generally reflected the dose infused. Despite such high concentrations (up to five times those previously observed in the treatment of hypovolemia (16,17)), no overt toxicity or altered dextran clearance was observed. In addition, serum Na, Cl and K levels were also maintained within acceptable limits, even following daily infusions at the MTD. Since the current proposed therapeutic dose of HSD is a single 4ml/kg dose, the present study indicates that few adverse effects would be encountered, even if the dose was doubled or multiple infusions given.

REFERENCES

1. Kramer GC, English TP, Gunther RA, Holcroft JW: Physiological mechanisms of fluid resuscitation with hyperosmotic/hyperoncotic solutions. In: Passmore JC, Reichard SM, Reynolds DG, Taber DL, eds. "Perspectives in Shock Research: Metabolism, Immunology, Mediators and Models". New York: Alan R. Liss, Inc. 1989; 311-320.
2. Hands R, Holcroft JW, Perron PR, Kramer GC: Comparison of peripheral and central infusion of 7.5% NaCl/6% dextran 70. Surgery 1988; 103:684-689.
3. Chudnofsky CR, Dronen SC, Syverud SA, Zink BJ, Hedges JR: Intravenous fluid therapy in the prehospital management of hemorrhagic shock: Improved outcome with hypertonic saline/6% Dextran-70 in a swine model. Am J Emerg Med 1989; 7:357-363.
4. Maningas PA: Resuscitation with 7.5% NaCl in 6% dextran-70 during hemorrhagic shock in swine: Effects on organ blood flow. Crit Care Med 1987; 15:1121-1126.
5. Holcroft JW, Vassar MJ, Perry CA, Gannaway WL, Kramer GC: Perspectives on clinical trials for hypertonic saline/dextran solutions for the treatment of traumatic shock. Brazilian J Med Biol Res 1989; 22:291-293.
6. Halvorsen L, Gunther RA, Holcroft JW: Dose response characteristics of hypertonic saline dextran solutions, Eur Surg Res, 1990, in press.
7. Pascual JMS, Watson JC, Runyon DE, Clifford CB, Kramer GC: Sodium and fluid loads during resuscitation of hemorrhagic shock using isotonic and hypertonic saline dextran solutions. Circ Shock 1990; 31:68.
8. Gruber UF: Blood Replacement. Berlin: Springer-Verlag, 1969.

9. Hunt H: Relationships between the chemical and physicochemical properties of dextran and its physicochemical effects. In: Derrick JR, Guest MM, Charles CE, Thomas C, eds. Dextran Current Concepts of Basic Actions and Clinical Applications. Springfield, IL: Charles C. Thomas Publishers. 1971; 3-26.
10. Arturson G, Wallenius G: The renal clearance of dextran of different molecular sizes in normal humans. Scand J Clin Lab Invest 1964; 1:81-86.
11. Arturson G, Granath K, Thoren L, Wallenius G: The renal excretion of low molecular weight dextran. Acta Chir Scand 1964; 127:543-551.
12. Arturson G, Granath K, Grotte G: Intravascular persistence and renal clearance of dextran of different molecular sizes in normal children. Arch Dis Child 1966; 41:168-171.
13. Leypoldt JK, Frigon RP, DeVore KW, Henderson LW: A rapid renal clearance methodology for dextran. Kidney Internat 1987; 31:855-860.
14. Harrison JH: Dextran as a plasma substitute with plasma volume and excretion studies on control patients. Ann Surg 1954; 139:137-142.
15. Thoren L: The dextrans-Clinical data. Develop Biol Standard 1980; 48:157-167.
16. Dubick MA, Summary JJ, Ryan BA, Wade CE: Dextran concentrations in plasma and urine following administration of 6% Dextran-70/7.5% Na Cl to hemorrhaged and euvoletic conscious swine. Circ Shock 1989; 29:301-310.
17. Dubick MA, Summary JJ, Wade CE: Plasma Clearance and tissue distribution of dextran following infusion of hypertonic saline/dextran to euvoletic and hemorrhaged rabbits. Circ Shock 1990; 31: 66.

18. Zaucha GM, Frost DF, Omaye ST, Clifford CB,
Korte DW Jr: Fourteen day subacute
intravenous toxicity study of hypertonic
saline/Dextran-70 and its constituents in
beagle dogs. Letterman Army Institute of
Research Institute Report #404, November
1989.

19. Zaucha GM, Frost DF, Omaye ST, McKinney LA,
Peare MJ, Korte DW Jr: Fourteen-day subacute
intravenous toxicity study of hypertonic
saline/Dextran-70 and its constituents in New
Zealand White rabbits. Letterman Army
Institute of Research Report #405, November,
1989.

20. Roe JH: The determination of dextran in blood
and urine with anthrone reagent. J Biol Chem
1954; 208:889-896.

21. Nilsson G, Nilsson K: Molecular weight
distribution determination of clinical
dextran by gel permeation chromatography. J
Chromatogr 1974; 101:137-153.

22. Remington RD, Schork MA: Statistics with
Applications to the Biological and Health
Sciences. Englewood Cliffs: Prentice Hall
Inc., 1970.

23. Maningas PA, DeGuzman LR, Tillman FJ, Hinson
CS, Priegnitz KJ, Volk KA, Bellamy RF. Small-
volume infusion of 7.5% NaCl in 6% Dextran 70
for the treatment of severe hemorrhagic shock
in swine. Ann Emerg Med 1986; 15 (10): 1131-
1137.

24. Velasco IT, Pontierri V, Rocha e Silva M.
Hyperosmotic NaCl and severe hemorrhagic
shock. Am J Physiol 1980; 239: H664-H673.

25. Wade CE, Hannon JP, Bossone CA, Hunt MM,
Loveday JA, Coppes R, Gildengorin VL.
Resuscitation of conscious pigs following
hemorrhage: Comparative efficacy of small-
volume resuscitation. Circ Shock 1989; 29:
193-204.

Dubick et al. -- 12

26. Arturson G: The change of molecular weight distribution of infused dextran, Scand J Clin Lab Invest 1965; 17(Suppl 86): 69-79.

Acknowledgement

The authors thank Jacqueline Y. Green for technical assistance and Mr. Donald L. Calkins for preparation of the manuscript.

Table 1
Hematocrits and Serum Na, K, Cl in Dogs Infused with
20ml/kg of HSD or D-70.

		DAY						
		0	0.25	1	2	3	7	14
Hct (%)	HSD	45±2	44±1	44±2	45±2	45±1	44±2	45±2
	D-70	45±2	45±2	44±2	46±3	46±1	46±4	46±2
Na (Meq/l)	HSD	152±2	157±1*	152±1	152±1	152±3	151±1	145±2
	D-70	152±2	151±2	152±2	152±2	151±1	149±1	150±1
K (Meq/l)	HSD	5.2±0.1	4.1±0.1*	4.7±0.1	4.9±0.1	5.0±0.2	5.2±0.2	4.8±0.2
	D-70	5.1±0.2	5.1±0.1	4.8±0.2	4.9±0.2	4.8±0.2	4.8±0.2	4.8±0.2
Cl (Meq/l)	HSD	110±1	116±2	112±1	110±2	113±2	112±1	109±4
	D-70	113±1	114±1	113±1	111±1	113±1	114±1	113±1

*Data expressed as mean ± S.E. from 4 dogs/group

*p<0.05 from time 0 value.

Table 2

Serum Dextran Concentrations in Dogs Infused
with 20ml/kg of HSD or Dextran-70

<u>DAY</u>	<u>HSD (n=4)</u>	<u>D-70 (n=4)</u>
0.25	864±29	991±34*
1	671±64	674±43
2	261±60	333±47
3	132±12	154±15
7	ND ²	ND
14	ND	ND

¹Data expressed as mean ±S.E. of mg/dl.

²ND- not detectable

*p<0.05 from HSD group

Table 3

Hematocrits and Serum Na, K, Cl Concentrations in Dogs and Rabbits
Infused Daily with HSD or D-70

		0	1	2	3	7	14
Dogs (nz6) (Daily Infusion of 20ml/kg)	HCT (%)						
	HSD	50±1	45±1*	46±1	44±1*	42±1*	42±3*
	D-70	48±1	46±1	44±1*	42±1*	38±1*	37±1*
	Na (Meq/l)						
	HSD	153±1	156±2	152±1	151±1	152±1	151±1
Rabbits (n=10) (Daily Infusion of 16ml/kg)	D-70	154±1	155±2	154±2	148±4	152±1	150±1
	K (Meq/l)						
	HSD	4.9±0.2	4.7±0.1	4.6±0.1	4.8±0.1	4.4±0.1	4.6±0.1
	D-70	4.9±0.1	4.7±0.1	4.7±0.1	4.6±0.2	4.4±0.1	4.6±0.1
	Cl (Meq/l)						
Dogs (nz6) (Daily Infusion of 20ml/kg)	HSD	114±1	120±2	117±1	116±1	117±1	118±1
	D-70	116±1	118±1	119±1	117±1	119±1	118±1
	HCT (%)						
	HSD	33±1	31±1	29±1	27±1*	25±1*	24±1*
	D-70	34±1	31±1	28±1*	27±1*	26±1*	25±1*
Rabbits (n=10) (Daily Infusion of 16ml/kg)	Na (Meq/l)						
	HSD	150±2	150±1	148±1	149±1	147±1	146±1
	D-70	150±1	149±1	148±1	148±1	146±1	147±1
	K (Meq/l)						
	HSD	4.1±0.1	4.2±0.2	4.3±0.1	4.2±0.1	4.1±0.1	4.5±0.2
Dogs (nz6) (Daily Infusion of 20ml/kg)	D-70	3.8±0.1	4.0±0.1	4.0±0.2	4.2±0.1	4.2±0.2	4.1±0.2
	Cl (Meq/l)						
	HSD	112±1	112±1	114±1	114±1	112±1	112±1
	D-70	115±1	114±1	114±1	114±1	113±1	114±1

Data expressed as mean ±SE
* p < 0.05 from time 0 value




Fig 1. Serum dextran concentrations in euvoletic dogs infused daily with 12, 16, or 20 ml/kg HSD or D-70. Data represents mean \pm S.E. of 4 animals at each time point. Different superscript denotes significant difference ($p < 0.05$).




Fig 2. Serum dextran concentration in euvoletic rabbits infused daily with 8,12 or 16 ml/kg HSD or D-70. Data represent mean \pm S.E. of 4-6 determinations at each time point. Different superscript denotes significant difference ($p < 0.05$).




Fig 3. Molecular weight distribution of dextran in serum from rabbits infused daily with 16ml/kg of HSD (closed circles) or Dextran-70 (open squares).

Legend To Figures

- Fig 1. Serum dextran concentrations in euvoletic dogs infused daily with 12, 16, or 20 ml/kg HSD or D-70. Data represents mean \pm S.E. of 4 animals at each time point. Different superscript denotes significant difference ($p < 0.05$).
- Fig 2. Serum dextran concentration in euvoletic rabbits infused daily with 8, 12 or 16 ml/kg HSD or D-70. Data represent mean \pm S.E. of 4-6 determinations at each time point. Different superscript denotes significant difference ($p < 0.05$).
- Fig 3. Molecular weight distribution of dextran in serum from rabbits infused daily with 16ml/kg of HSD (closed circles) or Dextran-70 (open squares).

OFFICIAL DISTRIBUTION LIST

Commander
US Army Medical Research
& Development Command
ATTN: SGRD-RMS/Mrs. Madigan
Fort Detrick, MD 21701-5012

Defense Technical Information Center
ATTN: DTIC/DDAB (2 copies)
Cameron Station
Alexandria, VA 22304-6145

Office of Under Secretary of Defense
Research and Engineering
ATTN: R&AT (E&LS), Room 3D129
The Pentagon
Washington, DC 20301-3080

DASG-AAFJML
Army/Air Force Joint Medical Library
Offices of the Surgeons General
5109 Leesburg Pike, Room 670
Falls Church, VA 22041-3258

HQ DA (DASG-ZXA)
WASH DC 20310-2300

Commandant
Academy of Health Sciences
US Army
ATTN: HSHA-CDM
Fort Sam Houston, TX 78234-6100

Uniformed Services University of
Health Sciences
Office of Grants Management
4301 Jones Bridge Road
Bethesda, MD 20814-4799

US Army Research Office
ATTN: Chemical and Biological
Sciences Division
PO Box 12211
Research Triangle Park, NC 27709-2211

Director
ATTN: SGRD-UWZ-L
Walter Reed Army Institute of Research
Washington, DC. 20307-5100

Commander
US Army Medical Research Institute
of Infectious Diseases
ATTN: SGRD-ULZ-A
Fort Detrick, MD 21701-5011

Commander
US Army Medical Bioengineering Research
and Development Laboratory
ATTN: SGRD-UBG-M
Fort Detrick, Bldg 568
Frederick, MD 21701-5010

Commander
US Army Medical Bioengineering
Research & Development Laboratory
ATTN: Library
Fort Detrick, Bldg 568
Frederick, MD 21701-5010

Commander
US Army Research Institute
of Environmental Medicine
ATTN: SGRD-UE-RSA
Kansas Street
Natick, MA 01760-5007

Commander
US Army Research Institute of
Surgical Research
Fort Sam Houston, TX 78234-6200

Commander
US Army Research Institute of
Chemical Defense
ATTN: SGRD-UV-AJ
Aberdeen Proving Ground, MD 21010-5425

Commander
US Army Aeromedical Research
Laboratory
Fort Rucker, AL 36362-5000

AIR FORCE Office of Scientific
Research (NL)
Building 410, Room A217
Bolling Air Force Base, DC 20332-6448

USAF School of Aerospace Medicine
Document Section
USAFSAM/TSKD
Brooks Air Force Base, TX 78235-5301

Head, Biological Sciences Division
OFFICE OF NAVAL RESEARCH
800 North Quincy Street
Arlington, VA 22217-5000

Commander
Naval Medical Command-02
Department of the Navy
Washington, DC 20372-5120